Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma

ConclusionEncoBini is associated with reduced costs and increased QALYs, dominating other targeted double combination therapies (DabraTrame, VemuCobi) for patients with BRAF V600-mutant MM in France. EncoBini is a highly cost-effective intervention in MM.
Source: The European Journal of Health Economics - Category: Health Management Source Type: research